Group One Trading
PRLD icon

Group One Trading’s Prelude Therapeutics PRLD Stock Holding History

Group One Trading’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Buy
+3,900
New +$10.2K ﹤0.01% 6201

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Group One Trading's PRLD Position: Q1 2026 in Review

Group One Trading increased its Prelude Therapeutics (PRLD) stake by 681% in Q1 2026, buying an estimated $8.93K and bringing the position to 3,907 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6200.

Group One Trading first reported a position in PRLD in Q3 2024 and has held it in 7 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Group One Trading held 3,907 shares of Prelude Therapeutics worth $13.4K as of Q1 2026.
  • Group One Trading bought 3,407 Prelude Therapeutics shares in Q1 2026, an estimated $8.93K.
  • Prelude Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6200 holding.
  • Group One Trading first reported a position in Prelude Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.